IDENTICAL
CLINICAL PROFILE

EXPANDED ACCESS

Authorized generics are therapeutically equivalent to the brand-name drug

Authorized generics are identical to the reference brand-name drug in both active and inactive ingredients. The name and packaging of an authorized generic differ from that of the branded product.

Options when prescribing an authorized generic:

  • Continue to write the brand name (ie, write "EPCLUSA" for sofosbuvir/velpatasvir for appropriate patients)
    —The authorized generic on formulary will be substituted for the branded drug in states with mandatory generic substitution laws. In states with permissive substitution laws, pharmacies will substitute the authorized generic per instruction from payers
  • Write the authorized generic name (ie, sofosbuvir/velpatasvir)

Please see full Prescribing Information for sofosbuvir/velpatasvir and ledipasvir/sofosbuvir, including BOXED WARNING.

This information is intended for US healthcare providers only.

ASEGUA and the ASEGUA logo are trademarks of Asegua Therapeutics LLC. EPCLUSA, HARVONI, SUPPORT PATH and GILEAD are trademarks of Gilead Sciences, Inc., or one of its related companies and are used by permission.

©2019 Asegua Therapeutics LLC. All rights reserved. AGPP0017 08/19

Asegua Therapeutics LLC is an affiliate of Gilead Sciences, Inc.